Federated Hermes Inc. Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Federated Hermes Inc. acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 124,620 shares of the company’s stock, valued at approximately $1,973,000.

A number of other large investors also recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after acquiring an additional 46,041 shares during the period. SG Americas Securities LLC bought a new stake in Keros Therapeutics during the fourth quarter valued at about $388,000. Barclays PLC grew its stake in Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Keros Therapeutics in the fourth quarter worth about $461,000. Finally, American Century Companies Inc. lifted its position in shares of Keros Therapeutics by 10.5% during the fourth quarter. American Century Companies Inc. now owns 328,920 shares of the company’s stock valued at $5,207,000 after buying an additional 31,251 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 0.5 %

Keros Therapeutics stock opened at $12.18 on Monday. The stock has a 50-day moving average price of $10.91 and a 200 day moving average price of $30.62. The company has a market capitalization of $494.05 million, a price-to-earnings ratio of -2.34 and a beta of 1.39. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Piper Sandler cut their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Wells Fargo & Company reduced their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Finally, Scotiabank decreased their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.